SalaryGuide
SalariesCompaniesJobs
AboutPricingBlogFor Employers

Marketing jobs

2 marketing jobs

Acadia Pharmaceuticals logo
5 hrs ago

Sr. Manager, HCP Marketing (Health Systems & Long-Term Care)

Acadia Pharmaceuticals

San Diego, CA (Hybrid)Full time$143K/yr – $178K/yr
Acadia Pharmaceuticals logo
1 day ago

Sr. Manager, HCP Marketing (Health Systems & Long-Term Care)

Acadia Pharmaceuticals

Princeton, NJ (Hybrid)$143K/yr – $178K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

2 jobs
Acadia Pharmaceuticals logo

Sr. Manager, HCP Marketing (Health Systems & Long-Term Care)

Acadia Pharmaceuticals

San Diego, CA (Hybrid)

$143K/yr - $178K/yrIn-houseFull-timeSenior level8+ years exp.
5 hrs ago
Acadia Pharmaceuticals logo

Sr. Manager, HCP Marketing (Health Systems & Long-Term Care)

Acadia Pharmaceuticals

Princeton, NJ (Hybrid)

$143K/yr - $178K/yrIn-houseSenior level8+ years exp.
1 day ago
Acadia Pharmaceuticals logo
Acadia Pharmaceuticals

Sr. Manager, HCP Marketing (Health Systems & Long-Term Care)

San Diego, CA (Hybrid)

$143K/yr – $178K/yrSenior Level8+ years expFull time

Posted 5 hrs ago

  • Job
  • Company
  • Salaries
  • People
  • Funding
  • Audience
  • News
  • Links

Job Description

Responsibilities

  • Health Systems Marketing
  • - Serve as the primary marketing partner to the Health Systems team, developing account-based resources that help HSMs engage IDNs, COEs, hospitals, and key institutions to improve access and appropriate use of Nuplazid.
  • - Build value and access materials anchored in RWE, HEOR, and HCRU data to support the health-system value story and address barriers to adoption.
  • - Collaborate with the Health Information and Technology team to develop tools that support EHR interventions, medication transitions-of-care, and discharge order-set discussions within Centers of Excellence and IDNs, in partnership with Health Systems, Medical, and Compliance.
  • - Create account-planning resources that help the field prioritize accounts and advance systematic opportunities.
  • - Coordinate congress- and KOL-related engagement materials relevant to health systems, in partnership with the Associate Director, Brand Development & KOL Engagement.
  • Long-Term Care Marketing (supporting the LTC sales team)
  • - Act as the dedicated marketing partner to the LTC sales team, delivering the promotional materials and field tools required to drive appropriate Nuplazid use across SNF and ALF settings.
  • - Own development and maintenance of LTC-specific core visual aids (CVAs), reprints, leave-behinds, and derivative field materials tailored to LTC prescribers
  • - Develop LTC in-service decks, account-planning resources, and facility-directed tools that support engagement with Medical Directors, Directors of Nursing (DONs), consultant pharmacists, and administrators.

Requirements

  • Bachelor’s degree in marketing, health care, life sciences, business administration, or a related field;
  • A minimum of 8 years of progressively responsible experience in pharmaceutical or biotech marketing (Senior Manager level); 5+ years may be considered at the Manager level.
  • Prior HCP marketing experience is required (e.g., promotional/NPP materials, CRM, field tools, congress support).
  • The description also notes experience supporting Health Systems / account-based marketing (IDNs, COEs, hospitals) and/or Long-Term Care (SNF/ALF) channels; however, the latter is marked as strongly preferred.

Preferred

  • MBA or advanced degree a plus.
  • Experience supporting Health Systems / account-based marketing (IDNs, COEs, hospitals) and/or Long-Term Care (SNF/ALF) channels strongly preferred.
  • Launch and new-product commercialization experience preferred.
  • Knowledge of neurology/neuropsychiatry therapeutics and the Neurology, Psychiatry, PCP, and LTC HCP market preferred.

Benefits

  • Medical, dental, and vision insurance
  • Employer-paid life, disability, business travel and EAP coverage
  • 401(k) Plan with a fully vested company match 1:1 up to 5%
  • Employee Stock Purchase Plan with a 2-year purchase price lock-in
  • 15+ vacation days
  • 13 -15 paid holidays, including office closure between December 24th and January 1st
  • 10 days of paid sick time
  • Paid parental leave benefit
  • Tuition assistance
Acadia Pharmaceuticals logo

Acadia Pharmaceuticals

3.1 Glassdoor

At Acadia, our mission is to turn scientific promise into meaningful innovation that makes the difference for underserved neurological disorders and rare disease communities around the world. Our commercial portfolio includes FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with early-stage programs that address other unmet patient needs.

Founded in 1993
San Diego, California, USA
1K employees (57 in marketing)
Acadia.com
43% recommend to a friend
49% CEO approval

Salaries

Posted range

$143K/yr – $178K/yr

Taken straight from the job posting.

See all Acadia Pharmaceuticals salaries

Marketing Team

Marketing Team Size
57 (6% of company)
Median Career Experience
20 years
Median Tenure
1.8 years
Marketing Roles Posted (Last 30 Days)
1

People

Marketing Leadership

Katie Kolator
Katie Kolator
Executive Director Consumer Marketing - Rare Disease
At the company for 1 year
Aine Scibelli
Aine Scibelli
Sr. Director Consumer Marketing
At the company for 1 year 2 months
Marc Haskins
Marc Haskins
Associate Director, Regional Marketing Liaison, Rare Disease
At the company for 1 year 5 months
Jeremy Wright
Jeremy Wright
Associate Director Regional Marketing Liaison South East
At the company for 1 year 5 months

Funding

Total Funding
$811.7M
Last Raise
$287.5M
Post IPO Equity, 7 years ago

Funding History

  • Sep 2019
    Post IPO Equity • $287.5M
  • Nov 2018
    Post IPO Equity • $316.2M
  • Jan 2013
    Post IPO Equity • $86.4M

Headcount Trend

Current headcount: ~1K

Recent News

ACADIA Pharmaceuticals (ACAD) Names A New Chief People Officer, Is It Still Below Fair Value?
Jul 11, 2026 • Yahoo Finance
Is ACADIA Pharmaceuticals (ACAD) Still Undervalued After The Daybue Win?
Jul 10, 2026 • Yahoo Finance
ACADIA Pharmaceuticals (ACAD) Stock Looks Undervalued After A 21% Run
Jul 9, 2026 • simplywall.st
Acadia Pharmaceuticals appoints Carl Segerstorm as CPO
Jul 6, 2026 • legacy.thefly.com
Canaccord reiterates Acadia Pharmaceuticals stock rating on Q1 results
Jul 4, 2026 • Investing.com
ACAD stock eyes best day in over a year as CHMP recommends approval for rare nerve disorder drug in Europe
Jul 1, 2026 • MSN
ACADIA Pharmaceuticals (ACAD) In Focus As Europe Backs Daybue And Undervalued View Holds
Jun 30, 2026 • simplywall.st
ACAD Maintains Buy Rating -- Price Target Raised to $30.00 by B of A Securities
Jun 30, 2026 • GuruFocus
H.C. Wainwright reiterates Acadia Pharmaceuticals stock rating on EU progress
Jun 30, 2026 • Investing.com
ACAD stock eyes best day in over a year as CHMP recommends approval for rare nerve disorder drug in Europe
Jun 30, 2026 • MSN
ACADIA Pharmaceuticals Price Target Raised to $35.00/Share From $32.00 by Citigroup
Jun 30, 2026 • Moomoo
Form 4 ACADIA Pharmaceuticals Inc For: 29 June By Investing.com
Jun 29, 2026 • Investing.com Canada
ACAD stock up as CHMP backs Daybu for EU approval in Rett syndrome
Jun 29, 2026 • MSN
Acadia Pharmaceuticals: Steady Commercial Progress, Remlifanserin Data In Focus
Jun 29, 2026 • Seeking Alpha
Acadia Pharmaceuticals (ACAD) Receives Positive CHMP Opinion for DAYBU Approval
Jun 29, 2026 • GuruFocus
ACAD Maintained by Canaccord Genuity -- Price Target Raised to $36.00
Jun 29, 2026 • GuruFocus
Mizuho reiterates Acadia stock rating after EU panel backs drug By Investing.com
Jun 29, 2026 • Investing.com Australia
Deutsche Bank Raises Price Target on ACADIA Pharmaceuticals to $37 From $32, Keeps Buy Rating
Jun 29, 2026 • marketscreener.com
Canaccord raises Acadia Pharmaceuticals price target on EU approval By Investing.com
Jun 29, 2026 • Investing.com India
Canaccord raises Acadia Pharmaceuticals price target on EU approval By Investing.com
Jun 29, 2026 • Investing.com UK
Mizuho reiterates Acadia stock rating after EU panel backs drug By Investing.com
Jun 29, 2026 • Investing.com India
Mizuho reiterates Acadia stock rating after EU panel backs drug
Jun 29, 2026 • Investing.com
Mizuho reiterates Acadia stock rating after EU panel backs drug By Investing.com
Jun 29, 2026 • Investing.com UK
Acadia Pharmaceuticals (ACAD) PT Raised to $36 at Canaccord
Jun 29, 2026 • StreetInsider
Acadia Pharmaceuticals (ACAD) PT Raised to $35 at Citi, Opens 90-Day Upside CW
Jun 29, 2026 • StreetInsider
ACAD Stock Up as CHMP Backs Daybu for EU Approval in Rett Syndrome
Jun 29, 2026 • Yahoo Finance
Canaccord raises Acadia Pharmaceuticals price target on EU approval
Jun 29, 2026 • Investing.com
Citi Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $35
Jun 29, 2026 • Moomoo
EMA reverses its stance on Acadia’s Rett syndrome therapy Daybu
Jun 29, 2026 • BioWorld Financial Watch
Why ACADIA Pharmaceuticals (ACAD) Is Up 17.1% After EMA Backs DAYBU For Rett Syndrome
Jun 27, 2026 • simplywall.st
Acadia Pharmaceuticals (ACAD) Shares Surge After EMA Panel Endor
Jun 27, 2026 • GuruFocus
Acadia Pharmaceuticals stock surges 6.75% as CHMP backs Rett syndrome drug, Acadia Pharmaceuticals announces
Jun 26, 2026 • Traders Union
Mizuho reiterates Acadia stock rating after EU panel backs drug By Investing.com
Jun 26, 2026 • Investing.com Australia
Acadia Pharmaceuticals stock rallies after EU panel supports Rett syndrome medicine approval
Jun 26, 2026 • Traders Union
Mizuho reiterates Acadia stock rating after EU panel backs drug By Investing.com
Jun 26, 2026 • Investing.com South Africa
Mizuho reiterates Acadia stock rating after EU panel backs drug By Investing.com
Jun 26, 2026 • Investing.com Nigeria
ACAD Stock Eyes Best Day In Over A Year As CHMP Recommends Approval For Rare Nerve Disorder Drug In Europe
Jun 26, 2026 • Stocktwits
Acadia Pharma Stock Jumps After European Panel Reverses Course On Rett Syndrome Therapy
Jun 26, 2026 • Benzinga
Acadia Pharmaceuticals (ACAD) Sees Significant Price Surge
Jun 26, 2026 • GuruFocus
ACAD Stock Eyes Best Day In Over A Year As CHMP Recommends Approval For Rare Nerve Disorder Drug In Europe
Jun 26, 2026 • Yahoo Finance
Baird reiterates Acadia stock rating on Rett syndrome drug approval By Investing.com
Jun 26, 2026 • Investing.com South Africa
ACADIA Pharmaceuticals Stock Soars Over 12% After EU Regulators Reverse Course on Rett Syndrome Drug
Jun 26, 2026 • International Business Times Australia
Baird reiterates Acadia stock rating on Rett syndrome drug approval
Jun 26, 2026 • Investing.com
Acadia wins EU backing for Rett syndrome drug (ACAD:NASDAQ)
Jun 26, 2026 • Seeking Alpha
Acadia Pharmaceuticals Stock (ACAD) Jumps on a Positive CHMP Review
Jun 26, 2026 • TipRanks
Acadia receives positive CHMP opinion for DAYBU in Rett Syndrome
Jun 26, 2026 • grafa.com
CHMP recommends approval of Acadia’s Rett syndrome treatment in EU
Jun 26, 2026 • Investing.com UK
Mizuho reiterates Acadia stock rating after EU panel backs drug By Investing.com
Jun 26, 2026 • Investing.com Canada
Mizuho reiterates Acadia stock rating after EU panel backs drug
Jun 26, 2026 • Investing.com
Acadia Pharmaceuticals shares rise 14% on European drug review By Investing.com
Jun 26, 2026 • Investing.com South Africa
Acadia Pharmaceuticals shares rise 14% on European drug review By Investing.com
Jun 26, 2026 • Investing.com Canada
Acadia Pharmaceuticals shares rise 14% on European drug review By Investing.com
Jun 26, 2026 • Investing.com UK
Acadia Pharmaceuticals (ACAD) Receives Positive Opinion for Dayb
Jun 26, 2026 • GuruFocus
Acadia Pharmaceuticals: Daybu recommended for approval in EU by CHMP
Jun 26, 2026 • TipRanks
Acadia Pharmaceuticals stock rises on EU drug approval recommendation By Investing.com
Jun 26, 2026 • Investing.com South Africa
CHMP recommends approval of Acadia’s Rett syndrome treatment in EU By Investing.com
Jun 26, 2026 • Investing.com Canada
DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP
Jun 26, 2026 • Yahoo! Finance Canada
Why Acadia Pharmaceuticals Stock Is Soaring Today
Jun 26, 2026 • The Motley Fool
On second try, Acadia drug gets nod from European regulators
Jun 26, 2026 • BioPharma Dive
Why Acadia Pharmaceuticals Stock Is Soaring Today
Jun 26, 2026 • Yahoo Finance
Acadia's Rett Syndrome Drug Nears EU Approval After Regulatory Reversal
Jun 26, 2026 • BriefGlance
EU regulator backs Acadia's DAYBU for Rett syndrome
Jun 26, 2026 • Stock Titan
ACADIA Pharmaceuticals strategy under review, shares tracked against biotech peers
Jun 22, 2026 • Ad-hoc-news.de
ACADIA Pharmaceuticals Inc (ACAD) Risk Assessment: Volatility, Financial Risk & Investment Risk
Jun 18, 2026 • TradingKey
ACADIA Pharmaceuticals Inc (ACAD) Financial Health: Profitability & Balance Sheet Analysis
Jun 18, 2026 • TradingKey
ACADIA Pharmaceuticals Inc (ACAD) Earnings Forecast: Future EPS & Revenue Growth Estimates
Jun 16, 2026 • TradingKey
ACADIA Pharmaceuticals stock (US0042251084): earnings momentum and pipeline focus in neuroscience
Jun 10, 2026 • AD HOC NEWS
Parkinson’s Support Group Meeting Friday, June 12, In Warsaw
Jun 10, 2026 • InkFreeNews.com
A Look At ACADIA Pharmaceuticals (ACAD) Valuation As Shares Show Mixed Recent Momentum
Jun 9, 2026 • simplywall.st
ACADIA Pharmaceuticals (ACAD) Holds Steady Near Support With Modest Uptick - Anchored VWAP
Jun 8, 2026 • newsline.com
ACADIA Pharmaceuticals (ACAD) Holds Steady Near Support With Modest Uptick - RSI Oversold Picks
Jun 8, 2026 • newsline.com
A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Recent Share Price Weakness
Jun 7, 2026 • Yahoo Finance
Acadia Pharmaceuticals stock edges higher to $21.72 as AcadiaPharma promotes Parkinsons study event
Jun 5, 2026 • Traders Union
Technical Reactions to ACAD Trends in Macro Strategies
Jun 2, 2026 • Stock Traders Daily
ACAD Stock Price, Quote & Chart | ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD)
May 29, 2026 • ChartMill
Principal Accounting Officer At ACADIA Pharmaceuticals Sells $114K Of Stock
May 28, 2026 • Benzinga
[Form 4] ACADIA PHARMACEUTICALS INC Insider Trading Activity
May 27, 2026 • Stock Titan
Form 144 lists 3,857 performance shares and ESPP lots for ACAD (NASDAQ: ACAD)
May 26, 2026 • Stock Titan
Acadia boosts ‘More To Parkinson's’ campaign with Ryan Reynolds, Parkinson’s voices
May 26, 2026 • Fierce Pharma
Oppenheimer Initiates ACADIA Pharmaceuticals(ACAD.US) With Hold Rating, Announces Target Price $23
May 22, 2026 • Moomoo
Acadia Pharmaceuticals’ SWOT analysis: stock faces EU hurdle By Investing.com
May 22, 2026 • Investing.com Nigeria
Assessing ACADIA Pharmaceuticals (ACAD) Valuation After Pipeline Progress And Product Rollouts
May 21, 2026 • simplywall.st
ACADIA Pharmaceuticals Spotlights Alzheimer’s Psychosis Pipeline, NUPLAZID and DAYBUE Growth
May 19, 2026 • Yahoo Finance
ACADIA Pharmaceuticals Spotlights Alzheimer’s Psychosis Pipeline, NUPLAZID and DAYBUE Growth
May 19, 2026 • The Globe and Mail
ACADIA Pharmaceuticals stock (US0042251084): biotech player in focus after recent price swings
May 19, 2026 • AD HOC NEWS
Acadia teams up with Ryan Reynolds on ‘More to Parkinson’s’ initiative
May 18, 2026 • Drug Store News
How ACADIA’s (ACAD) Solid Q1 Revenue and Pipeline Update Has Changed Its Investment Story
May 17, 2026 • simplywall.st
How ACADIA’s (ACAD) Solid Q1 Revenue and Pipeline Update Has Changed Its Investment Story
May 16, 2026 • Sahm
ACADIA Pharmaceuticals stock (US0042251084): Biotech decline amid CNS focus
May 14, 2026 • AD HOC NEWS
Biopharmas look to China, elsewhere for partnerships, R&D (ACAD:NASDAQ)
May 14, 2026 • Seeking Alpha
Shareholders In ACADIA Pharmaceuticals (NASDAQ:ACAD) Should Look Beyond Earnings For The Full Story
May 14, 2026 • Yahoo Finance
ACADIA Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
May 11, 2026 • Moomoo
Earnings Miss: ACADIA Pharmaceuticals Inc. Missed EPS By 58% And Analysts Are Revising Their Forecasts
May 11, 2026 • Yahoo Finance
ACADIA Pharmaceuticals stock (US0042251084): Focus on CNS drug pipeline and commercial execution
May 8, 2026 • AD HOC NEWS
What ACADIA Pharmaceuticals (ACAD)'s Earnings Miss, EU Setback and R&D Transition Means For Shareholders
May 8, 2026 • Yahoo Finance
Acadia Pharmaceuticals Q1 2026 Financial Results: DAYBUE and NUPLAZID Sales Growth, Reaffirms Full Year Guidance
May 7, 2026 • Minichart
Is ACADIA Pharmaceuticals (ACAD) Offering Value After A 45% One Year Share Price Gain?
May 7, 2026 • simplywall.st
ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth
May 7, 2026 • TradingView
ACADIA Pharmaceuticals Signals Confident Path After Q1 Call
May 7, 2026 • TipRanks
ACADIA Pharmaceuticals earnings up next: Can drug sales sustain momentum?
May 6, 2026 • Investing.com

Links

Acadia.comLinkedInX (Twitter)Crunchbase